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Mutations in the Histone Modifier
PRDM6 Are Associated with Isolated
Nonsyndromic Patent Ductus Arteriosus
Na Li,1,9 Lakshman Subrahmanyan,1,9 Emily Smith,1,9 Xiaoqing Yu,2 Samir Zaidi,2 Murim Choi,2
Shrikant Mane,2 Carol Nelson-Williams,2 Mohaddeseh Behjati,3 Mohammad Kazemi,4
Mohammad Hashemi,4 Mohsen Fathzadeh,1 Anand Narayanan,1 Likun Tian,1 Farhad Montazeri,1
Mitra Mani,1 Michael L. Begleiter,5 Brian G. Coon,1 Henry T. Lynch,6 Eric N. Olson,7 Hongyu Zhao,2
Ju¨rgen Ruland,8 Richard P. Lifton,1,2 and Arya Mani1,2,*
Nonsyndromic patent ductus arteriosus (PDA) is a common congenital heart defect (CHD) with both inherited and acquired causes, but
the diseasemechanisms have remained elusive. Using combined genome-wide linkage analysis and whole-exome sequencing (WES), we
identified independent mutations in PRDM6, which encodes a nuclear protein that is specific to vascular smooth muscle cells (VSMC),
has histone methyl transferase activities, and acts as a transcriptional suppressor of contractile proteins. In vitro assays showed that the
mutations cause loss of function either by intracellular redistribution of the protein and/or by alteration of its methyltransferase activ-
ities. Wild-type embryonic ductus arteriosus (DA) exhibited high levels of PRDM6, which rapidly declined postnatally as the number of
VSMCs necessary for ductus contraction increased. This dynamic change suggests that PRDM6 plays a key role inmaintaining VSMCs in
an undifferentiated stage in order to promote their proliferation and that its loss of activity results in premature differentiation and
impaired remodeling of the DA. Our findings identify PRDM6 mutations as underlying genetic causes of nonsyndromic isolated PDA
in humans and implicates the wild-type protein in epigenetic regulation of ductus remodeling.Introduction
Patent ductus arteriosus (PDA [MIM: 607411]) is the sec-
ond most common congenital heart defect (CHD) and af-
fects up to 5,000 live births in the United States.1,2 During
fetal life, the ductus arteriosus (DA) shunts blood from the
pulmonary artery to the aorta, bypassing the lungs. Its
abrupt closure at birth, which establishes the mature circu-
latory pattern, is the result of a protracted and dramatic
process of vascular remodeling. According to results from
animal studies, the remodeling of the DA is a complex pro-
cess involving the migration of neural-crest-derived cells
into the subendothelial space and their transformation to
vascular smooth muscle cells (VSMCs), as well as extracel-
lular-matrix accumulation and formation of subintimal
cushions. Subsequently, an increase in vasoactive peptides
such as endothelin A1, a decrease in prostaglandin E2
levels,3,4 and ultimately VSMC contraction result in
closure of the vessel.5,6 Experimental in vivo and in vitro
studies have shown that failure in any step of this process
can result in persistent patency of the DA and thus lead to
pulmonary arterial hypertension, pulmonary edema, and
congestive heart failure in humans.7
The molecular mechanisms underlying DA remodeling
in humans are not understood. The disease can be ac-1Cardiovascular Research Center, Department of Internal Medicine, Yale Unive
CT 06520, USA; 2Department of Genetics, Yale University School of Medicine,
diovascular Research Institute, Isfahan University of Medical Sciences, Isfahan
5School of Medicine, University of Missouri – Kansas City, Kansas City, MO
Creighton University, Omaha, NE 68131, USA; 7Department of Molecular Bio
USA; 8Institute fu¨r Klinische Chemie und Pathobiochemie, Klinikum Rechts d
9These authors contributed equally to this work
*Correspondence: arya.mani@yale.edu
http://dx.doi.org/10.1016/j.ajhg.2016.03.022.
1082 The American Journal of Human Genetics 98, 1082–1091, June
 2016 American Society of Human Genetics.quired, and congenital rubella syndrome is the best-
known cause.8 The increased familial recurrence, the
autosomal-dominant inheritance of rare syndromic and
nonsyndromic PDA, and the development of the trait in
transgenic mice are strong pieces of evidence supporting
the sizable role of genetics in the development of this
condition. These studies have implicated the central
role of neural-crest-derived VSMCs and genes regulating
their function in remodeling of the DA.9,10 Genetic deter-
minants of nonsyndromic PDA in humans are not
known. We ascertained 35 individuals affected by non-
syndromic familial PDA and extended their kindreds.
Except for a large African-American kindred with suffi-
cient power for linkage, all other affected individuals
were white subjects from nuclear kindreds (Figure S1).
All were products of healthy full-term pregnancies;
maternal rubella had been excluded. They all had under-
gone cardiac catheterization at the time of recruitment
and had no other vascular anomalies. All but one were
living subjects, and all had undergone surgical or
transvenous device closure for isolated PDA. Combined
genome-wide linkage analysis, whole-exome sequencing
(WES), and gene-set enrichment analysis (GSEA) were
performed for the identification of disease-associated
mutations.rsity School of Medicine and Howard HughesMedical Institute, New Haven,
New Haven, CT 06520, USA; 3Isfahan Cardiovascular Research Center, Car-
81746, Iran; 4Isfahan University of Medical Sciences, Isfahan 81746, Iran;
64108, USA; 6Department of Preventative Medicine, School of Medicine,
logy, University of Texas Southwestern Medical Center, Dallas, TX 75390,
er Isar, Technische Universita¨t Mu¨nchen, Munich 81675, Germany
2, 2016
Material and Methods
Ascertainment and Recruitment of PDA Subjects
The study protocol was approved by the Human Investigation
Committee of the Yale University School of Medicine, the institu-
tional review boards at the University of Nebraska and University
of Kansas, and the Committee for Ethics and Research Conduction
at the Isfahan Cardiovascular Research Center. Consent was ob-
tained from all subjects. Records were reviewed for documentation
of diagnosis, age of diagnosis, clinical findings, treatment, and
family history. Subjects underwent physical examinations, and
venous blood samples were collected. Blood samples were pro-
cessed locally by either traditional phenol-chloroform extraction
or salt extraction.
Analysis of Linkage
Genome-wide analysis of linkage was performed with the Affyme-
trix GeneChip 10K Array. Additional markers were typed in
selected intervals for maximizing informativeness for the linked
interval. These markers were genotyped by PCR with specific fluo-
rescently labeled oligonucleotide primers and genomic DNA as a
template. The resulting amplified products were fractionated by
electrophoresis on denaturing polyacrylamide gels with an
ABI3700 instrument and analyzed with GeneScan 2.1 and Geno-
typer 1.1.1 software. Two independent investigators scored all ge-
notypes. Analysis of linkage was performed with GeneHunter 2.1.
For allele frequencies,mean frequencies of 300 ethnicallymatched
control individuals were used.
Targeted Sequence Capture
Genomic DNA was captured on exomes at the W.M. Keck Facility
at Yale University as described earlier.2 The Roche NimbleGen
2.1M Human Exome Array covers 34.0 Mb of genomic sequence
and approximately 180,000 exons of 18,673 protein-coding genes.
In brief, DNAwas fragmented and ligated to linkers and then frac-
tionated by agarose gel electrophoresis. Extracted DNA was ampli-
fied by PCR and hybridized to the capture arrays. Bound genomic
DNA was eluted, purified, and amplified by ligation-mediated
PCR. The PCR products were purified and subjected to DNA
sequencing on the Illumina platform.
Sequencing
Captured libraries were sequenced on the Illumina Genome
Analyzer, and then image analysis and base calling were per-
formed. Sequence reads were mapped to the human reference
genome (UCSC Genome Browser hg19) with the MAQ program
SAMtools. Resulting sequence data were processed with MAQ
software. SAMtools was used to detect single-nucleotide variants,
which were subsequently filtered against the reference genome as
described earlier.11 Filters were applied against published data-
bases. A Perl-based computer script was used for annotating
variants according to their effect on the protein, novelty, conser-
vation, and tissue expression. Variants were considered non-
conservative if the substituted amino acid was conserved in all
species or had a maximum of one conserved substitution. Sanger
sequencing was carried out for most variants of interest,
including all variants in PRDM6 (PR domain 6). Gene Ontology
(GO) was used for GSEA. Variants were filtered if they had allele
frequencies greater than 0.01% in the Exome Aggregation Con-
sortium (ExAC) Browser and if they were considered not
damaging by PolyPhen and SIFT software. Mutations in genesThe Americwith expression levels 2 SDs below average in the heart, cardio-
myocytes, smooth muscle cells, and aorta were excluded from
analysis. The expression level from each tissue was based on Affy-
metrix GNF_U133A (as were expression data from the UCSC
Genome Browser). The 1000 Genomes Project and an exome
database of 2,000 healthy white subjects were used as controls.
Population structure was excluded by principal-component anal-
ysis (Figure S3).
Mutagenesis and Adenoviral Constructs
pcDNA3.1 plasmid containing mouse wild-type Prdm6 with
FLAG tag was kindly provided by Dr. Eric Olson. PRDM6 amino
acid substitutions p.Arg549Gln (c.1646G>A) and p.Cys263Ser
(c.788G>C) were generated with the QuikChange II Site-Directed
Mutagenesis Kit (Agilent Technologies) according to the manu-
facturer’s instructions. Adenovirus expression plasmid pAd/
CMV/V5-DEST (Invitrogen, Life Technologies) separately encod-
ing FLAG-PRDM6-WT, FLAG-PRDM6-p.Arg549Gln, and FLAG-
PRDM6-p.Cys263Ser was prepared with Gateway Cloning tech-
nology (Life Technologies) according to the manufacturer’s
instructions.
Antibodies
Antibodies to a-smooth muscle actin (a-SMA), myosin heavy
chain 11 (MYH11), CD31, GM130, importin-b, and H3 pan were
purchased from Abcam. Antibodies to phalloidin and GAPDH
were purchased from Cell Signaling Technology. Antibodies to
H4K20me2, H3K9me2, and H4 pan were purchased from EMD
Millipore. Antibodies to PRDM6, FLAG, and Calnexin were pur-
chased from Novus Biologicals, Sigma-Aldrich, and Enzo Life Sci-
ences, respectively.
Immunofluorescence Staining
Wild-type mouse DAs were micro-dissected and embedded in
optimal cutting temperature (OCT) compound at three different
developmental stages: embryonic days 14.5 (E14.5) and 17.5
(E17.5) and postnatal day 0.5 (P0.5).12 The differences in fluores-
cence intensities were compared with MATLAB software.
Cells were seeded in a glass-bottom petri dish. HEK293 cells were
transfected with Lipofectamine 2000, and human aortic VSMCs
were infected with adenovirus. 48 hr later, cells were fixed in 4%
paraformaldehyde and were permeabilized in 0.1% Triton X-100
and blocked with 3% BSA in PBS after appropriate washes. Speci-
mens were subsequently incubated with primary antibodies fol-
lowed by fluorescence-conjugated secondary antibodies at room
temperature and were mounted with ProLong Gold Antifade
Mountant with DAPI (Invitrogen). Images were acquired with a
Zeiss LSM510 confocal microscope.
Immunoblotting
Human aortic VSMCs (passage 3) transfected with adenovirus
were lysed with cell-lysis buffer (Cell Signaling Technology)
for extraction of total protein or with the EpiQuik Total
Histone Extraction Kit (EpiGentek) for obtaining histone protein
according to the manufacturers’ instructions. Lysates were pro-
cessed and applied to SDS-PAGE and further immunoblotted
with target primary antibodies followed by appropriate horse-
radish-peroxidase-conjugated secondary antibodies. Enhanced
chemiluminescence reagents were applied for blot develop-
ment. ImageJ software was used for quantification of the band
intensities.an Journal of Human Genetics 98, 1082–1091, June 2, 2016 1083
GSEA
GSEA is a systematic analysis frequently used for identifying dis-
ease-causing mutations for complex traits.13–15 For this analysis,
we assigned to GO pathways all non-conservative deleterious var-
iants with allele frequencies less than 0.01% (<1:10,000) in the
ExAC Browser. After exclusion of population stratification, 2,000
exomes of European descent were used as controls. Subsequently,
we used Fisher’s exact test to compare the ratio of identified vari-
ants and total number of bases sampled in a given pathway to
the same ratio obtained from the control population. p values
for these comparisons were corrected for multiple comparisons
as previously described, and p < 2.7 3 104 was considered
significant. The estimated odds ratio of these variants for the trait
was calculated. We rejected the null hypothesis that these path-
ways could be over-represented in a small sample by chance by
applying a randomization test of exome variants of 32 randomly
selected individuals from the control exome database with a
p value of 4 3 1051.Statistical Analysis
All in vitro experiments were carried out in triplicate. Data are ex-
pressed as means5 SEM. Comparisons between two groups were
performed with Fisher’s exact test. Statistical significance is
defined as p < 0.05. The expected number of genes with more
than one previously unreported non-conservative and deleterious
mutation was determined by Monte Carlo simulation (104 itera-
tions) specifying the total number of nonsynonymous and delete-
rious mutations and 21,000 genes of observed coding length.Results
Linkage Analysis Maps the Disease-Associated
Mutation to 5q23 in a Large PDA-Affected Kindred
Kindred PDA-101 (Figure 1A) is a large African-American
family, first reported in 1965.16 To our knowledge, this is
the largest reported nonsyndromic-PDA-affected kindred
with sufficient power for linkage (see Supplemental
Note). In sum, a total of nine individuals with PDA were
identified in the family; all had a definitive diagnosis of
PDA, were born at term as the product of normal gestation,
and could trace their ancestry to a single pair of founders.
We found no subjects with PDA or other CHD anomalies in
other branches of the kindred, arguing against multifacto-
rial determination (complex trait). These findings strongly
supported autosomal-dominant transmission of PDA with
incomplete penetrance, thereby prompting further genetic
study.
In order to map the disease-associated mutation in PDA-
101, we performed genome-wide SNP genotyping in all
family members by using the Affymetrix GeneChip 10K
Array according to the manufacturer’s protocol. We used
two pre-specified models of the trait locus to compare the
inheritance of marker alleles to the inheritance of PDA:
(1) a conservative model specified the trait locus as auto-
somal dominant with 90% penetrance, a phenocopy rate
of 1%, and a disease allele frequency of 0.001, and (2) a
stringent model specified 99% penetrance, 0.1% pheno-
copies, and an allele frequency of 0.0001. Pairwise analysis1084 The American Journal of Human Genetics 98, 1082–1091, Juneof linkage demonstrated positive LOD scores for linkage to
a cluster of markers in chromosomal region 5q23. The
maximum pairwise LOD score was 2.57 (at a recombina-
tion fraction [q] of 0 with the marker rs2081914). Multi-
point analysis confirmed linkage to this chromosomal
segment, yielding a maximum LOD score of 3.12 for link-
age of the trait locus (Figure 1B), PDA1, to rs2081914 at
q ¼ 0. No other interval in the genome yielded a LOD
score greater than 1.0, providing strong evidence that
PDA1 lies in the 5q23 interval. Changing estimates of
penetrance of the trait locus from 80% to 95% and the
frequency of mutant genes did not have substantial effects
on the LOD score or the disease locus (data not shown).
Linkage analysis of only affected individuals yielded
similar results, such that no other genomic interval was
shared among all studied subjects. Review of the segre-
gating haplotypes demonstrated that all affected individ-
uals share a haplotype in this interval (Figure 1A). These
findings indicate significant linkage of PDA to 5q23 in
this kindred.
AMissense Mutation in PRDM6 Underlies Autosomal-
Dominant PDA
The LOD-1 support interval, which approximates the 95%
confidence interval for the disease locus, spans a10 cM
(10 Mb) interval flanked by loci rs721065 and rs2108652
and contains 42 annotated genes. Four remotely related
members of this kindred (subjects III-2, IV-9, III-11, and
IV-6; Figure 1A) were screened for mutations by WES on
the Roche NimbleGen 2.1M Human Exome Array. We
achieved 95% coverage of the reference genome at a min-
imum depth of 20 reads. After quality filtering, we found a
mean of 18,000 exomic variations per individual. We used
SAMtools and the Genome Analysis Toolkit to detect poly-
morphic sites. The remainder (an average of 400 variants)
were filtered against 1000 Genomes, the National Heart,
Lung, and Blood Institute (NHLBI) Exome Sequencing
Project (ESP) Exome Variant Server (ESP6500, including
2,300 African Americans), the ExAC Browser, and the
Yale 5,000 exome database (including 2,000 healthy con-
trol individuals). These variants were further filtered by
conservation as follows. If the identified amino acid
change was seen in 0 or 1 of 44 vertebrate species, the
change was considered non-conservative. After this
filtering, there remained only one single non-conservative
PRDM6 variant (c.1646G>A [p.Arg549Gln] [GenBank:
NM_001136239.1]) that tightly linked to the location of
the maximum LOD score within the shared haplotype
and perfectly segregated with the disease (Figure 1C).
Other mutations in the recombination interval were either
intronic or common polymorphisms (Table S1). Arg549
resides in the protein’s fourth zinc-finger domain, which
is critical for nuclear localization of the protein and is
highly conserved in orthologs from humans to sea anem-
ones (Figure 1D). The mutation was present in all other
affected individuals, was absent in all unaffected family
members and all exome databases (including the ExAC2, 2016
Figure 1. PRDM6 p.Arg549Gln in a Large PDA-Affected Kindred
(A) Pedigree PDA-101 is shown. Individuals with PDA are indicated by black symbols, individuals without PDA are shown as unfilled
symbols, and individuals with unknown PDA status are shown with partially filled squares. Circles represent females, squares represent
males, and symbols with a slash through them indicate deceased subjects. Haplotypes on 5q23 are shown under each individual.
(B) Multipoint LOD scores for linkage of PDA to 5q23. SNPs tightly linked to the location of PRDM6 in the LOD-1 region are shown. The
maximum LOD score is indicated, and the location of PRDM6 is shown. The LOD score peak occurs at q¼ 0 withmarker rs2081914, and
the LOD-1 interval spans 10 cM.
(C) The DNA sequence of a segment flanking c.1646G>A in PRDM6 is shown from an unaffected kindred member (left) and a hetero-
zygous mutation carrier (right). This single-base substitution (asterisk) changes the wild-type arginine to glutamine at amino acid 549
(p.Arg549Gln).
(D) A portion of the PRDM6 amino acid sequence flanking Arg549 is shown from diverse vertebrate species.Browser), and was predicted to be deleterious by PolyPhen
and SIFT.
Examination of the exome data in the remaining PDA-
affected individuals (n ¼ 34) led to the identification of
two additional non-conservative mutations in PRDM6
(c.788G>C [p.Cys263Ser] and c.1385A>G [p.Gln462Arg])
in two unrelated subjects (Figures 2A and 2B). Amino
acid substitution p.Gln462Arg was also present in the
affected daughter of the subject. No segregation analysis
could be carried out in the kindred affected by
p.Cys263Ser, because the affected mother and maternal
grandfather of the index subject had died before sampleThe Americcollection. Statistical analysis using two random control
subjects from the NHLBI Exome Variant Server showed
that recurrent mutations in this gene in this number
of samples is unlikely to have occurred by chance
(p < 4.74 3 106, Monte Carlo simulation). It is note-
worthy that no single nonsynonymous mutation in
PRDM6 was identified in exomes of our 2,000 healthy
white control individuals. Amino acid substitutions
p.Cys263Ser and p.Gln462Arg were also absent in all other
public exome databases (including the ExAC Browser) and
were predicted to be deleterious by PolyPhen and SIFT.
Cysteine at codon 263 and glutamine at codon 462 arean Journal of Human Genetics 98, 1082–1091, June 2, 2016 1085
Figure 2. Independent Non-conservative Mutations of PRDM6 in Subjects with PDA
(A and B) A pedigree with a DNA segment flanking the PRDM6 c.788G>Cmutation (resulting in p.Cys263Ser) and a portion of the pro-
tein flanking Cys263 in diverse vertebrate species are shown in (A). A pedigree with a DNA segment flanking the PRDM6 c.1385A>G
mutation (resulting in p.Arg549Gln) and a portion of the protein flanking Gln462 in diverse vertebrate species are shown in (B). Indi-
viduals with PDA are indicated by black symbols, individuals without PDA are shown as unfilled symbols, and individuals with
(legend continued on next page)
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Figure 3. The Effect of PRDM6 Amino
Acid Substitutions on Its Nuclear Locali-
zation
Immunofluorescence staining of wild-type
PRDM6, PRDM6 p.Arg549Gln (p.R549Q),
and p.Cys263Ser (p.C263S) in HEK293
cells. Whereas wild-type PRDM6 and
p.Cys263Ser were localized in the nucleus,
p.Arg549Gln was predominantly localized
in the cytoplasm. Colors are as follows:
blue, DAPI; green, phalloidin; and red,
PRDM6 with FLAG tag. Scale bars
represent 7 mm.highly conserved among all orthologs and paralogs (Fig-
ures 2A and 2B). Cys263 resides in the highly conserved
SET domain, which is involved in chromatin regulation
and determines how the enzyme catalyzes the transfer of
the methyl from S-adenosyl methionine to the histone res-
idue.17 A schematic of the PRDM6 domains and the loca-
tion of the three independent amino acid substitutions
are shown in Figure 2C.
PRDM6 c.1646G>A Impairs Nuclear Localization of
the Encoded Protein
PRDM6 is a nuclear protein that functions as a histone
methyltransferase and suppresses the transcription of
VSMC contractile proteins.18 We overexpressed con-
structs encoding wild-type PRDM6 and PRDM6 variants
p.Arg549Gln and p.Cys263Ser, which lie in critical do-
mains in HEK293 cells and human aortic VSMCs. Arg549
resides in a protein segment that has previously been
shown to be critical for nuclear localization.18 Further-
more, in silico analysis designated this amino acid as an
RNA binding site. Functional in vitro characterization of
PRDM6 p.Arg549Gln in HEK293 cells and human aortic
VSMCs showed that the variant protein significantly
loses its capability for nuclear localization (Figures 3
and 4). Co-staining with markers of the endoplasmic
reticulum (calnexin), Golgi apparatus (GM130), and mito-
chondria (Cox IV) and the nuclear transporter importin-b
excluded retention of the protein on any of these organ-
elles (Figure S2). We subsequently used an adenovirus
vector to overexpress DNA encoding wild-type PRDM6
and PRDM6 variants p.Arg549Gln and p.Cys263Ser inunknown PDA status are shownwith partially filled squares. Circles represent females, square
through them indicate deceased subjects.
(C) A schematic of PRDM6 with functional domains and the location of the three independ
are not drawn to scale. ZF denotes zinc finger.
The American Journal of Human Ghuman aortic VSMCs. Immunofluo-
rescence (IF) showed that, compared
to the empty vector, wild-type
PRDM6 suppressed MYH11, but
PRDM6p.Arg549Gln andp.Cys263Ser
largely failed to reduce its amount
(Figure 4). Given that the function ofthe wild-type protein is to silence the transcription of
VSMCs, this finding suggests loss of function.
PRDM6 Substitutions Exhibit Loss of Function in
Histone Modification and Suppression of VSMC
Contractile Proteins
PRDM6 has been implicated in histone lysine methylation
and transcriptional suppression of contractile protein
in smooth muscle cells.18 We examined the effects of
the amino acid substitution on H3K9 and H4K20 dimethy-
lation in human aortic VSMCs by using an adenovirus
vector to overexpress DNA encoding wild-type PRDM6
and PRDM6 variants p.Arg549Gln and p.Cys263Ser.
Wild-type PRDM6 reduced dimethylation of H3K9
and increased dimethylation of H4K20, whereas both
variant PRDM6 proteins had completely opposite effects
(Figure 5A).
Immunoblot analysis revealed that PRDM6 p.Arg549Gln
and p.Cys263Ser were associated with higher amounts of
MYH11 and a-SMA than was the wild-type (Figure 5B).
Because PRDM6 amino acid substitutions might cause a
dominant-negative effect by altering dimerization, we as-
sessed this property of wild-type and variant PRDM6
in vitro by using native PAGE gel (Figure S4). No change
in dimerization was identified between wild-type and
variant PRDM6. These findings provide strong evidence
supporting the functional effects of the amino acid substi-
tutions and provide strong links to disease pathogenesis.
Interestingly, we also observed an increased burden of
mutations in other histone-modifying genes in the re-
maining PDA subjects. A GSEA (see Material and Methods)s representmales, and symbols with a slash
ent mutations are shown. Intronic regions
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Figure 4. The Effect of PRDM6 Amino
Acid Substitutions on MYH11 Cellular
Levels
Immunostaining demonstrates the locali-
zation of PRDM6 (red) in relationship to
the nucleus (blue) and the staining for
MYH11 in human aortic smooth muscle
cells. Cells infected with wild-type
PRDM6, PRDM6 p.Arg549Gln (p.R549Q),
and PRDM6 p.Cys263Ser (p.C263S) are
shown in the top, middle, and bottom
rows, respectively. Wild-type PRDM6 sup-
pressed MYH11. Substitution p.Arg549Gln
was largely retained in the cytoplasm,
whereas p.Cys263Ser was mainly ex-
pressed in the nucleus. In smooth
muscle cells overexpressing DNA encoding
p.Arg549Gln and p.Cys263Ser, MYH11
staining was comparable to that in non-
transfected cells. Dotted lines delineate
transfected cells. Scale bars represent
28 mm.revealed that previously unreported deleterious mutations
in histone-modification pathways (Tables S2 and S3) were
significantly associated with PDA in 15 of 32 affected indi-
viduals (estimated odds ratio ¼ 14.95, CI ¼ 8.63–25.50).
Although GSEA does not establish causality, the finding
is intriguing and relevant given a priori association be-
tween the histone modifier PRDM6 and PDA.
Evaluation of PRDM6 Amounts in DA Smooth Muscle
Cells
The pressing question is how reduced function of PRDM6
causes disease even though it results in higher amounts of
contractile proteins. We examined the amounts of PRDM6
in wild-type DA and aorta in different stages of develop-1088 The American Journal of Human Genetics 98, 1082–1091, Junement by IF. Examination of mouse DA in E14.5, E17.5,
and P0.5 embryos (Figure 6A) showed dynamic changes
in staining of PRDM6 in DA smoothmuscle cells—staining
was strong prenatally but declined rapidly postnatally
(Figure 6B)—whereas the aorta showed no significant
change in PRDM6 staining before or after birth (Figure 6C).
This reduction in the amount of ductus PRDM6 was not
due to increased apoptosis (Figure S5). Despite a previous
report, there was no detectable staining of PRDM6 in
CD31þ (endothelial) cells. Taken together, these findings
suggest that PRDM6 maintains VSMCs in an undifferenti-
ated state during embryonic life, a function most likely
required for their proliferation. The rapid postnatal decline
of PRDM6 amounts can also be explained for the necessaryFigure 5. The Effect of PRDM6 Amino
Acid Substitutions on the Amounts of
H4K20me2, H3K9me2, MYH11, and
a-SMA
Immunoblot shows the amounts of his-
tones H4K20me2 and H3K9me2 (A) and
MYH11 and a-SMA (B) in wild-type human
aortic VSMCs transfected with wild-type
PRDM6, PRDM6 p.Arg549Gln (p.R549Q),
and PRDM6 p.Cys263Ser (p.C263S). Cells
transfected with empty vector were used
as controls. The lower panel shows the rela-
tive intensities by densitometry. Error bars
denote the SEM.
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Figure 6. Dynamic Changes in PRDM6 Abundance in Mouse DA and Great Vessels
(A) H&E staining of the aorta (AO), ductus arteriosus (DA), and pulmonary artery (PA) at E14.5, E17.5, and P0.5.
(B and C) IF staining of PRDM6, a-SMA, and CD31 at E14.5, E17.5, and P0.5. (B) PRDM6 was detectable in smooth muscle cells, but not
in endothelia cells, of the DA at E14.15 and E17.5. Its amounts were diminished in the DA at P0.5. (C) PRDM6 was persistently detected
in smooth muscle cells of the aorta at all three embryonic stages without significant variation. Scale bars represent 37 mm.
(D and E) Relative intensities of PRDM6 in the DA (D) and aorta (E) at E14.5, E17.5, and P0.5 in sevenmice. L denotes lumen. Arrowheads
point toward PRDM6 staining. Error bars denote the SEM.
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VSMC differentiation enabling these cells to contract and
occlude DA lumen. PRDM6 loss of function in humans
and mice causes premature differentiation and reduced
proliferation of VSMCs, resulting in impaired cushion for-
mation and patency of the vessel. In conclusion, our study
has identified PRDM6 mutations as the underlying causes
of inherited nonsyndromic PDA and implies impaired
epigenetic regulation in the pathogenesis of PDA.Discussion
CHDs are the most common developmental defects in
newborns and children. Although their heritability is
well established, identification of their causal mutations
has been limited by their complex pattern of inheritance.
PDA is one the most common inherited CHDs and is also
seen as a result of environmental insults such as maternal
rubella infection. It is caused by impaired embryonic re-
modeling of the DA, a process that has been of great inter-
est because of its resemblance to pathological remodeling
of adult vessels. As a result, extensive studies have been car-
ried out to elucidate the underlying mechanism of DA re-
modeling, both in vivo and in vitro. Despite these efforts,
the pathophysiology of the nonsyndromic PDA in humans
has remained obscure. By using linkage analysis and WES,
we identified independent mutations in PRDM6 as the
underlying causes of isolated nonsyndromic autosomal-
dominant PDA.
The functional significance of the encoded amino acid
substitutions was established by the high conservation of
the mutated bases, in vitro functional studies, and tissue-
specific and dynamic changes of PRDM6 amounts in the
murine embryonic DA. Arg549 is a highly conserved
amino acid that resides in a protein region that has been
previously shown to play a critical role in the protein’s nu-
clear localization.18 It is also predicted to be a RNA binding
site by in silico analysis. Accordingly, in vitro analysis
showed that the p.Arg549Gln substitution impairs the nu-
clear localization of the protein and acts as a loss-of-func-
tion variant. Cys263, which is substituted by serine, is a
highly conserved amino acid that resides in the SET
domain, functionally critical for its methyl transferase ac-
tivities. Glu462, which is substituted by arginine, is also a
highly conserved amino acid and is predicted to be
damaging by SIFT and PolyPhen.
PRDM6 is a member of the PRDM family of transcrip-
tional repressors, which contain a PR domain and multiple
zinc-finger domains. It is abundantly present in the cardiac
outflow tract and the DA and is involved in epigenetic
regulation of VSMC contractile proteins.18 Interestingly,
several PDA-affected individuals showed evidence of
enrichment of previously unreported non-conservative
amino acid substitutions in other histonemodifiers (Tables
S2 and S3). Compared to PRDM6mutations, these variants
most likely impart much smaller effects on the trait given
that they occur mainly sporadically and occasionally1090 The American Journal of Human Genetics 98, 1082–1091, Junemore than once in each individual. Overall, our findings
prompt the question as to whether inherited or acquired
forms of PDA are caused by epigenetic dysregulation of
vascular genes.
PRDM6 functions as a transcriptional repressor of
myocardin, GATA-6, smooth muscle cell actins, and myo-
sins.18 These proteins are important for VSMC differentia-
tion and their development of contractile phenotypes.19
Thus, with the finding of PRDM6 mutations, we hypothe-
sized that PRDM6 loss of function results in early differen-
tiation of VSMCs and thus their reduced proliferation.
A rapid decline of PRDM6 in the wild-type DA suggests
that VSMC differentiation occurs in later developmental
stages to promote the contraction and sufficient PRDM6
amounts necessary for proliferation of these cells. Accord-
ingly, altered function of Tfap2b—the murine ortholog
of TFAP2B (MIM: 601601), the gene associated with
human syndromic PDA, known as Char syndrome (MIM:
169100)—also results in impaired development of the
VSMC layer and patency of the DA in mice.20 PDA has
been reported in a few subjects with thoracic aortic aneu-
rysm and rare genetic variants in MYH11 (MIM: 132900)
and ACTA2 (MIM: 611788).21,22 Structural analyses of the
aorta in these affected individuals have revealed large areas
of medial degeneration with very low VSMC content. In
this study, we found no coding variants in MYH11,
ACTA2, or JAG1 (MIM: 187500). To our knowledge, none
of these genes have been associated with isolated PDA.
In summary, our study establishes the key role of PRDM6
in regulation of VSMC plasticity during DA remodeling.
In vitro functional characterization of PRDM6 and its
impaired function and the identification of its epigenetic
targets are important steps toward discovering novel path-
ways for the development of drugs against diverse vascular
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